{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:58:29Z","timestamp":1790726309299,"version":"4.1.0"},"reference-count":86,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,7,20]],"date-time":"2020-07-20T00:00:00Z","timestamp":1595203200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Bispecific antibodies (bsAbs) have become an integral component of the therapeutic research strategy to treat cancer. In addition to clinically validated immune cell re\u2010targeting, bsAbs are being designed for tumor targeting and as dual immune modulators. Explorative preclinical and emerging clinical data indicate potential for enhanced efficacy and reduced systemic toxicity. However, bsAbs are a complex modality with challenges to overcome in early clinical trials, including selection of relevant starting doses using a minimal anticipated biological effect level approach, and predicting efficacious dose despite nonintuitive dose response relationships. Multiple factors can contribute to variability in the clinic, including differences in functional affinity due to avidity, receptor expression, effector to target cell ratio, and presence of soluble target. Mechanistic modeling approaches are a powerful integrative tool to understand the complexities and aid in clinical translation, trial design, and prediction of regimens and strategies to reduce dose limiting toxicities of bsAbs. In this tutorial, the use of mechanistic modeling to impact decision making for bsAbs is presented and illustrated using case study examples.<\/jats:p>","DOI":"10.1002\/cpt.1961","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T16:28:37Z","timestamp":1593016117000},"page":"528-541","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology"],"prefix":"10.1111","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0848-3230","authenticated-orcid":false,"given":"Alison","family":"Betts","sequence":"first","affiliation":[{"name":"Applied Biomath Concord Massachusetts USA"},{"name":"Division of Systems Biomedicine and Pharmacology Leiden Academic Centre for Drug Research Leiden The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1314-3484","authenticated-orcid":false,"given":"Piet H.","family":"van der Graaf","sequence":"additional","affiliation":[{"name":"Division of Systems Biomedicine and Pharmacology Leiden Academic Centre for Drug Research Leiden The Netherlands"},{"name":"Certara Canterbury UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,7,20]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.4.2.19000"},{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3363"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2012.07.001"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-018-0299-9"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.006"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1268307"},{"key":"e_1_2_10_7_1","volume-title":"Blincyto (blinatumomab) prescribing information","author":"Amgen","year":"2014"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2012.07.013"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12426"},{"key":"e_1_2_10_11_1","unstructured":"Sorger P.K.et al.Quantitative and systems pharmacology in the post\u2010genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms<https:\/\/www.nigms.nih.gov\/training\/documents\/systemspharmawpsorger2011.pdf> (2011)."},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0332-z"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.651"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-614636"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/2515135518763280"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.9.4882"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1272"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3654"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/LBA2019.2"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.07.062"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1396"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.8007"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000132"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.3002"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2017.09.001"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.393"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.4155\/fsoa-2017-0152"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja311795d"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1608820113"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2011.11.021"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12369"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1480299"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0657"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2007.10.002"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-017-0090-5"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2009.0627"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2013.07.017"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1141160"},{"key":"e_1_2_10_41_1","first-page":"4157","article-title":"Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays","volume":"52","author":"Kaufman E.N.","year":"1992","journal-title":"Cancer Res."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep40098"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat5775"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1696"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.2"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-416039-2.00004-5"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2016.1243055"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.73"},{"key":"e_1_2_10_49_1","first-page":"4423","article-title":"High levels of serum HER\u20102\/neu and YKL\u201040 independently reflect aggressiveness of metastatic breast cancer","volume":"9","author":"Jensen B.V.","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23689"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/12.suppl_1.S49"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.150896"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-735365"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.581"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12459"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1145"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.990"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.15406\/moji.2015.02.00052"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000436722.46675.4a"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2265"},{"key":"e_1_2_10_62_1","unstructured":"Hua F. Lin L. Betts A.M. Wille L. Burke J.&Apgar J.Bridging non\u2010clinical studies to clinical design using quantitative systems pharmacology model of T cell engaging bispecifics<https:\/\/www.eventscribe.com\/2019\/PharmSci360\/fsPopup.asp?efp=SUlFUEhHSFQ4MDkx&PosterID=240309&rnd=0.4667056&mode=posterinfo> (2019)."},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/1547691X.2020.1729902"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1995.4.433"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19960516)66:4<477::AID-IJC11>3.0.CO;2-5"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2017.09.002"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1574521"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1000976107"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1450710"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1457"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12381"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12662"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.07.034"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0956"},{"key":"e_1_2_10_76_1","doi-asserted-by":"crossref","unstructured":"Motte\u2010Mohs R.L.et al.MGD013 a bispecific PD\u20101 x LAG\u20103 dual\u2010affinity re\u2010targeting (DART\u00ae) protein with T\u2010cell immunomodulatory activity for cancer treatment. In American Association for Cancer Research Annual Meeting April 16\u201320 2016 New Orleans LA. Abstract 3217.","DOI":"10.1158\/1538-7445.AM2016-3217"},{"key":"e_1_2_10_77_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1462429"},{"key":"e_1_2_10_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.06.054"},{"key":"e_1_2_10_79_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9892-3"},{"key":"e_1_2_10_80_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0881-T"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.002"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0320(19960615)26:2<137::AID-CYTO7>3.0.CO;2-D"},{"key":"e_1_2_10_83_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23830"},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/12.1.73"},{"key":"e_1_2_10_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2016.08.001"},{"key":"e_1_2_10_86_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1310358"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1961","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1961","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1961","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1961","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:37:56Z","timestamp":1699364276000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,20]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1002\/cpt.1961"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1961","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,20]]},"assertion":[{"value":"2020-04-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}